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receptor has a higher affinity for PCP than for benzomorphans. The main pharmacological difference between the
two sites is that the a receptor binds haloperidol as well as
many other neuroleptic drugs, whereas the PCP receptor is
insensitive to neuroleptics.
Some light has been shed on the physiological function of
PCP and, possibly, a receptors: The PCP receptor may be
identical to a Na+ /Ca2" -type ion channel that is coupled to
the N-methyl-D-aspartate-type glutamate receptor, since it
has been shown that PCP and related drugs block this
channel (18). In addition, PCP and N-methyl-D-aspartate
binding sites have been shown to have a nearly identical
neuroanatomical distribution (19). The function of the a
receptor, on the other hand, is less clear. However, it has
been shown that ao receptor-selective drugs cause an increase in the electrically stimulated twitch response of
isolated guinea pig (20) and mouse (21) vasa deferentia; in
addition, it has been shown that ar receptor-selective drugs
cause an increase in the electrically stimulated release of
norepinephrine from the mouse vas deferens raising the
possibility that a receptors may be involved in stimulating
catecholamine release (21).
To characterize the molecular properties of the a receptor,
we have synthesized a radiolabeled photoaffinity ligand,

The r-type opiate receptor is a distinct bindABSTRACT
ing site in the brain that may mediate some of the psychotomimetic effects caused by benzomorphan opiates and phencyclidine in humans. We have developed a synthetic, highly
selective ligand for this receptor, 1,3-di-o-tolylguanidine
(DTG). To identify the binding protein(s) of the or receptor, we
have now synthesized a radiolabeled azide derivative of DTG,

1-(4-azido-2-methyl[6-3H]phenyl)-3-(2-methyl[4,6-3H]phenyl)guaidine ([3HIN3DTG). In guinea pig brain membrane binding assays conducted in the dark, [3H]N3DTG bound reversibly, selectively, and with high affinity (Kd = 10 nM) to v
receptors. The drug specificity profile of reversible [3H]N3DTG binding was identical to that of [3H]DTG and 3Hlabeled (+ )-3-(3-hydroxyphenyl)-N-(l-propyl)piperidine binding indicating that [3HJN3DTG is a selective cr receptor ligand.
Guinea pig brain membranes were photoaffinitylabeled with
[3HJN3DTG. NaDodSO4/PAGE of detergent-solubilized membrane extract identified a single 29-kDa radioactive band.
Sepharose Cl-6B gel chromatography of photolabeled brain
membranes solubilized with the nondenaturing detergent sodium cholate showed a radioactive complex with a Stoke's
radius of 4.6 nm (Mr, 150,000) that may represent the intact (F
receptor complex. NaDodSO4/PAGE of this complex showed
that the radiolabeled material was a 29-kDa polypeptide that
may be the binding subunit of the (r receptor. The specific (F
receptor photoaffinity ligand described here should be a useful
tool for purifying and characterizing the (F receptor.

1-(4-azido-2-methyl[6-3H]phenyl)-3-(2-methyl[4,6-3H]phenyl)guanidine ([3H]N3DTG), derived from the or receptor
ligand 1,3-di-o-tolylguanidine or 1,3-di-(2-methylphenyl)guanidine (DTG). We report here that [3H]N3DTG selectively labels a single polypeptide of M, 29,000 in guinea pig
brain membranes as determined by NaDodSO4/PAGE followed by fluorography. Under nondenaturing conditions on
a Sepharose 6B column this polypeptide elutes as part of a
M, 150,000 complex. These results suggest that the binding
subunit of the a receptor is a distinct, brain membraneassociated binding protein and that this binding protein, as
part of a larger complex, may participate in mediating some
of the central actions of drugs that interact with a receptors.

Synthetic morphine derivatives of the benzomorphan class
cause hallucinations, disorientation, drunkenness, and other
psychotomimetic effects in humans (1, 2). These effects are
similar to those seen in phencyclidine (PCP or "angel dust")
intoxication (3). In addition, benzomorphans and PCP have
similar behavioral and autonomic effects in animals (4-9).

The molecular characterization of the brain receptors with

which benzomorphans and PCP interact is of considerable
importance since the psychotomimetic symptoms caused by
these drugs are similar to those seen in paranoid schizophrenia. Indeed, PCP has been proposed to be a useful drug
model for schizophrenia (3).
Radioligand binding studies on rodent brain membrane
suspensions have identified the existence of two separate
drug binding sites that are candidates for mediating some of
the psychotomimetic effects of benzomorphans and PCP.
These binding sites are the or receptor (10-14) and the PCP
receptor, respectively (14-17). Both sites interact with PCP
and benzomorphans. However, the a, receptor has a higher
affinity for benzomorphans than for PCP, and the PCP

MATERIALS AND METHODS
Synthesis of N3-Labeled DTG and [3H]N3DTG. The synthe-

sis schemes used are shown in Fig. 1.

Synthesis of 1-(4-azido-2-methylphenyl)-3-(2-methylphenyl)guanidine (compound 8, Fig. 1). 1-(4-Amino-2methylphenyl)-3-(2-methylphenyl)guanidine (compound 6,
Fig. 1) was prepared from compounds 1 and 2 by way of
compound 3 (22) and then was converted into the dihydroAbbreviations: DTG, 1,3-di-(2-methylphenyl)guanidine or 1,3-di-o-

tolylguanidine; i3H]N3DTG, 1-(4-azido-2-methyl[6-3H]phenyl)-3-(2methyl[4,6_3Hjphenyl)guanidine; PCP, phencyclidine.
§To whom reprint requests should be addressed.
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Synthesis and structure of N3-labeled DTG and
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chloride, mp 285-2880C. A 412-mg (1.25 mmol) sample of the
dihydrochloride was dissolved in water (4 ml) and concentrated dihydrochloric acid (0.385 ml, 4.60 mmol). The solution was cooled in an ice bath, and solid NaNO2 (142 mg,
2.69 mmol) was added in a single portion. The now yellow
solution was stirred at 0C for 1 hr and then cooled to
- 10TC. Next, a solution of NaN3 (109 mg, 1.69 mmol) in
water (1.5 ml) was added dropwise over 15 min. The chilled
solution was allowed to stir for 45 min and then to warm to
25TC. This solution was extracted with ether, and then the
aqueous phase was basified with 5 M NaOH (1.54 ml, 7.6
mmol), causing a yellow precipitate to form. The mixture
was extracted with ether, and the combined extracts were
washed with brine, dried (MgSO4), and concentrated to
dryness to give an orange oil. This was dissolved in ethanol
(10 ml), and then water (8 ml) was added, precipitating the
crude azide (215 mg, 65%) as a tan powder, mp 116-118TC.
A 180-mg portion was crystallized from ethanol/water, 1:1
(vol/vol) (6 ml). The needle crystals were collected, dissolved in ethanol (2 ml), and filtered through a 0.5-cm
column of activated charcoal on a bed of Celite. On diluting
the filtrate with water (0.5 ml), the analytical sample of
compound 8 (34 mg; 12% based on compound 6) crystallized
as off-white needles, mp 123-1240C (dec). 1H NMR
(C2H302H) 2.269 (s, 3), 2.272 (s, 3), 6.848 (dd, 1, J = 2.7,
8.4 Hz), 6.914 (d, 1, J = 2.1 Hz), 7.004 (td, 1, J = 1.5, 7.2
Hz), 7.136-7.229 (m, 4); IR (KBr) 2123 cm - 1 (strong, azide).
Anal. Calcd. for C15H16N3: C, 64.27; H, 5.75; N, 29.98.
Found: C, 63.87; H, 5.59; N, 29.67.

Synthesis of J-(6-bromo-2-methyl4-nitrophenyl)-3-(4,6dibromo-2-methylphenyl)guanidine (compound 4, Fig. 1).
N-Bromosuccinimide (425 mg, 2.39 mmol) was added to a
stirred suspension of 1-(2-methyl-4-nitrophenyl)-3-(2methylphenyl)guanidine (compound 3, Fig. 1) [222 mg, 0.781
mmol; prepared as described (22)], in MeOH (3 ml) at 0°C.
After stirring for 2 hr the brown slurry was diluted with
MeOH (1 ml) and stirred at 25°C for 1 hr. Filtration gave a
brown solid (192 mg), a 131-mg portion of which was

2845

crystallized from acetone by dropwise addition of water, to
give compound 4 (77 mg, 28%) as brown needles, mp 198200°C. Sublimination of these crystals at 155-160'C/0.01
mm gave compound 4 (40 mg) as a bright yellow powder, mp
210-2130C. 1H NMR (C2H302H) / 2.357 (s, 3), 2.488 (s, 3),
7.444 (d, 1, J = 1.5 Hz), 7.669 (d, 1, J = 1.8 Hz), 8.033 (d,
1, J = 2.1 Hz), 8.267 (d, 1, J = 2.4 Hz). Anal. Calcd. for
C15H13Br3N4O2: C, 34.58; H, 2.52; N, 10.75. Found: C, 34.64;
H, 2.47; N, 10.65.
Synthesis of (4-amino-2-methyl[6-3IHJphenyl)-3-(2-methyl[4,6-3H]phenyl)guanidine (compound 5, Fig. 1). A 25-mg
sample of the tribrominated nitro derivative (compound 4)
was submitted to Amersham for catalytic reduction in the
presence of 50 Ci (1 Ci = 37 GBq) of 3H2 gas. This replaced
the bromide atoms by 3H and at the same time reduced the
nitro group to an amino group. Excess concentrated HCI
was added to convert the resulting 3H-labeled amine (compound 5) into its chemically more stable dihydrochloride for
storage. The sample was stored in ethanol/water, 1:1
(vol/vol), at - 70'C.
Two- to 5-mCi portions of the crude radioactive product
were purified by reversed-phase HPLC on a Vydac 218TP54
C18 column (The Separations Group, Hesperia, CA) by using
a 30-min linear gradient of 0-50% CH3CN in 0.1% trifluoroacetic acid. The flow rate was 1 ml/min, and 1-min
fractions were collected with a fraction collector. The HPLC
equipment consisted of two Waters model 510 pumps, a
Waters gradient controller, and a Kratos Spectroflow 757
flow-through spectrophotometer operating at 220 nm. A
UV-absorbing radioactive peak eluted at 15.2 min, identical
to the elution time of the unlabeled amine (compound 6) (22).
The specific radioactivity of the amine (compound 5) was
found to be 102 Ci/mmol, based on the amount of material
under the UV-absorbing peak as determined by spectrophotometry and on the radioactivity associated with this peak as
determined by liquid scintillation spectrometry.
Synthesis of [3HJN3DTG (compound 7, Fig. 1). A 2-mCi
portion of the HPLC-purified 3H-labeled amine (compound
5) was evaporated to dryness, dissolved in 40 ,ul of 3 M
acetic acid, and cooled to 0°C. A solution of 10 jig of NaNO2
in 2 ,ul of 3 M acetic acid was added. After incubation on ice
for 15 min, 10 ug of NaN3 in 2 ,ul of 3 M acetic acid was
added, and the reaction was allowed to proceed in the dark
on ice for another 15 min. The resulting solution was then
subjected to reversed-phase HPLC purification with the
same chromatography conditions described above for the
purification of the 3H-labeled amine (compound 5). A major
radioactive peak coincided with a major UV-absorbing peak
eluting at 26.6 min. The fraction containing this peak was
collected in subdued light and stored in the dark at -70°C
until used.
To confirm the identity of this peak, 1 mg of unlabeled
amine (compound 6) was subjected to a scaled-up azide
conversion protocol as described above. Reversed-phase
HPLC purification of the reaction mixture yielded a UVabsorbing peak with the same retention time as that of the
radiolabeled product. The 300-MHz 1H NMR spectrum of
this material was identical to that of the analytical sample of
unlabeled azide (compound 8).
or Receptor Reversible Binding Assays. The basic binding
assay protocol used to characterize the reversible binding of
[3H]N3DTG has been described (12). Briefly, frozen guinea
pig brains (Biotrol, Indianapolis) were homogenized with a
Polytron homogenizer in 10 vol (wt/vol) of ice-cold 0.32 M
sucrose. The homogenate was spun for 10 min at 900 x g at
4°C in a Sorvall RC5B centrifuge. The supernatant was
collected and recentrifuged at 40C at 13,700 x g for 40 min.
The pellet was washed with 50 mM Tris-HCI (pH 7.4) (Tris)
and centrifuged again at 13,700 x g. The final pellet was
resuspended in Tris at a protein concentration of 3 mg/ml
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and stored frozen at 70'C. For binding assays, the frozen
membrane suspension was thawed and diluted 1:6 with Tris.
To a 12 x 75 mm culture tube was added 800 pl of the
membrane suspension, 100,ul of [3H]N3DTG in Tris, and 100
tul of Tris alone or Tris with known concentrations of various
unlabeled drugs. The final protein concentration was 400
tug/ml. Nonspecific binding was defined as that remaining in
the presence of 10 p.M haloperidol. After incubation in the
dark at room temperature for 2 hr, the membrane suspension
was diluted to 5 ml and rapidly filtered over Whatman GF/B
glass fiber filters followed by two washes with 5 ml of Tris by
using a Brandel (Gaithersburg, MD) 48-well cell harvester.
Filters were dissolved in 10 ml of Cytoscint (Westchem
Products, San Diego, CA), and radioactivity was measured
in a liquid scintillation counter with an efficiency of 50%o.
Scatchard analyses were done on an IBM AT personal
computer by using the EBDA data analysis program (23).
Photoaffinity Labeling of Guinea Pig Brainv Receptors.
The brain membrane suspensions used for photoaffinity
labeling ofvr receptors were prepared as described above
except that the final protein concentration was 800,pg/ml.
The presence of protease inhibitors (1 mM EDTA, 0.1 mM
phenylmethylsulfonyl fluoride, leupeptin at 5 pug/ml, and
bacitracin at 2.5,pg/ml) throughout the membrane preparation and incubation had no effect on labeling efficiency or
specificity. In a typical experiment, 1-ml aliquots of membrane suspension were incubated in the dark for 2 hr at room
temperature with 10 nM [3HJN3DTG alone or in the presence
of various unlabeled drugs to determine specificity of photoaffinity labeling. The suspensions were then rapidly filtered through a 2.4-cm Whatman GF/B glass fiber filter by
using a Hoefer (San Francisco) FH224V filtration apparatus
and washed with two 5-ml aliquots of Tris. The filters were
then placed on ice and exposed to long wavelength (366 nm)
UV light by using a 500-W UV lamp (Sunjet 400T deluxe,
Electrolux-Kern GmbH, Gottingen, F.R.G.) at a distance of
10 cm for 15 min. Membrane proteins were solubilized from
the filters by incubating in 2 ml of either 0.2% NaDodSO4 or
20 mM sodium cholate in Tris for 4 hr at 4°C with constant
shaking. The detergent-solubilized material was then centrifuged at 105,000 x g for 1 hr.
NaDodSOJ/PAGE and Sepharose Cl-6B Chromatography.
Following photoaffinity labeling, NaDodSO4-solubilized
membrane proteins were subjected to electrophoresis in a
12% discontinuous gel (24). Gels were electrophoresed at 30
mA for 4 hr followed by fixing in a solution of 50%o (vol/vol)
methanol and 10% (vol/vol) acetic acid and staining with
Coomassie blue R-250. The fixed and stained gels were
impregnated with EN3HANCE (New England Nuclear) and
exposed to x-ray film (Kodak X-Omat AR). Alternatively,
the distribution of radioactivity in the gels was determined
by counting 5-mm gel slices after a 24-hr incubation in
Protosol (New England Nuclear) at 50°C. Gel permeation
chromatography of cholate-solubilized membrane proteins
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FIG. 2. Equilibrium saturation binding of [3H]N3DTG to guinea
pig brain membranes. Membranes were incubated in the dark for 2
hr at room temperature with various concentrations of ligand.
Values are means of triplicate determinations. (Inset) Scatchard plot

of saturation binding data.

binding. No difference in nonspecific binding was seen by
using 10 .uM DTG as nonspecific control. Equilibrium of
[3H]N3DTG binding was reached by 2 hr at room temperature. Equilibrium saturation binding analysis showed that
[3H]N3DTG bound saturably to guinea pig brain membrane
suspensions (Fig. 2). Scatchard analysis of the binding

resulted in a linear Scatchard plot with a KD of 10 nM and a
Bmax of 5.3 pmol/mg of protein.

A drug specificity profile of [3H]N3DTG binding by using
various unlabeled drugs considered to be typical cr-receptor
ligands (12) showed that [3H]N3DTG labels the same binding
sites as [3H]DTG: As shown in Table 1, the K, values of the
various drugs in displacing [3H]N3DTG binding were very
similar to those found for displacement by the same drugs of
[3H]DTG. Indeed, the correlation of the K, values of the
various drugs in the two binding assays was high (r = 0.97).
A high correlation (r = 0.92) was also observed between
ligand 3H-labeled (+)-3-(3[3H]N3DTG and the
hydroxyphenyl)-N-(1-propyl)piperidine (data not shown).

a-selective

Table 1. K, values of or receptor active drugs against [3H]N3DTG
and [3H]DTG

K;, nM
Drug

N3-labeled DTG
Haloperidol
DTG
Perphenazine
(+ )-Pentazocine
(- )-Pentazocine
(+ )-Butaclamol
(- )-Butaclamol
(+)-3-PPP
(-)-3-PPP

Sepharose Cl-6B column

(Pharmacia) equilibrated at room temperature in Tris containing 20 mM sodium cholate at a flow rate of 20 ml/hr.
Fractions (2.5 ml) were collected, 1-ml aliquots were dissolved in 12 ml of Aquasol scintillation fluid (New England
Nuclear), and radioactivity was measured.

(+ )-Cyclazocine
(- )-Cyclazocine

(+ )-SKF 10,047
(-)-SKF 10,047
TCP

PCP
RESULTS AND DISCUSSION

In the dark [3H]N3DTG bound reversibly, selectively, specifically, saturably, and with high affinity to guinea pig brain
membrane suspensions. In a typical binding assay with
95,000 cpm of [3H]N3DTG, 15,000 cpm was bound, whereas
in the presence of 10 p.M haloperidol 1500 cpm remained
bound indicating that specific binding was .90%o of total

(1988)

Triflupromazine

Chlorpromazine
Amitriptyline
Imipramine

Against

Against

[3H]N3DTG

[3H]DTG
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±
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±

±
±
±
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2
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9
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1%
32
2
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2554 + 223
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±
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±
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Values are mean SEM,
and (- )-3-(3-hydroxyphenyl)-N-(1-propyl)piperidine; TCP, N-[1-(2thienyl)cyclohexyl]piperidine; SKF 10,047, N-allylnormetazocine.
±

*Kd
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Thus, under reversible binding conditions, [3H]N3DTG is a
highly specific a- receptor radioligand.
Having established the binding selectivity of [3H]N3DTG,
we tested the ability of [3H]N3DTG to covalently label oreceptor binding protein(s) in guinea pig brain membranes.
Incubation of brain membranes with [3H]N3DTG followed
by washing and exposure to UV light was performed.
Solubilization of the derivatized membranes followed by
NaDodSO4 electrophoresis and fluorography of the gels
revealed that the photolabel was selectively incorporated
into a single band of Mr 29,000 (Fig. 3).
Labeling of this band was unaffected by the presence of 10
ttM morphine in the incubation mixture but could be completely blocked by the a- ligands haloperidol, (+)-3-(3-hydroxyphenyl)-N-(1-propyl)piperidine, DTG, or (+)-pentazocine at 10,4M (Fig. 3). Dopamine, serotonin, scopolamine,
and y-aminobutyric acid were ineffective at blocking incorporation of label at the same concentration (data not shown).
When the sodium cholate-solubilized photolabeled brain
membrane extracts were chromatographed on a Sepharose
Cl-6B sizing column in 20 mM sodium cholate as described
above, the radioactivity was associated with a major peak
containing molecules with a Stoke's radius of 4.6 nm (Mr,
150,000, uncorrected for bound detergent) (Fig. 4). Some
noncovalently associated [3H]N3DTG or a breakdown product eluting in the total volume of the column was also
detected. When the material under the Mr 150,000 peak was
concentrated and subjected to NaDodSO4/PAGE, and the
radioactivity in the gel slices was measured, the radioactivity
was predominantly associated with a peak of Mr 29,000 (Fig.
5). No Mr l150,000 peak was seen under those conditions.
These results demonstrate that the binding subunit of the
a- receptor is a distinct Mr 29,000 polypeptide. This polypeptide is apparently membrane bound as detergent is required
to solubilize it. This is an important observation since it
raises the possibility that this subunit may participate in
mediating some of the actions of a-receptor-active drugs in
the brain.
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FIG. 4. Sepharose Cl-6B chromatography of photoaffinity labeled guinea pig brain membrane proteins showing specific labeling
of a Mr -150,000 complex. Proteins were solubilized after labeling
with 20 mM sodium cholate/Tris. Membranes were incubated with
10 nM [3H]N3DTG in the presence (A) or absence (o) of 10 ,uM
haloperidol. Molecular weight standards were tryptophan, carbonic
anhydrase (29 kDa), bovine serum albumin (66 kDa), alcohol dehydrogenase (150 kDa), apoferritin (443 kDa), and blue dextran
(Sigma).

The results presented here also suggest that the Mr 29,000
protein is part of a larger protein complex, since under
nondenaturing conditions, this polypeptide migrates as part
of a Mr o150,000 protein complex. Treatment with NaDodSO4 causes separation of the Mr 29,000 polypeptide from its
other associated protein(s). This finding suggests that the areceptor binding subunit is noncovalently assoc tted with
other subunit(s). No disulfide bridges seem to
involved
here since NaDodSO4 electrophoresis of photol; -d membrane extract without prior reduction shows i
ame Mr
is (data
29,000 polypeptide as seen under reducing con
not shown). It will be important to determine wl
- the Mr
CD150,000 complex corresponds to the function. .ctive areceptor.
The a- receptor whose binding subunit has bet
-ntified
here can be pharmacologically distinguished fra
le PCP
receptor (25, 26). Both binding sites are cant tes for
mediating some of the psychotomimetic effects benzomorphans and PCP. A 3H- and azido-labeled PCP-derived
photoaffinity ligand has been shown to label a number of
polypeptides in rat brain membrane suspensions (27). These
included a 90-kDa polypeptide whose labeling was potently
blocked by PCP-related drugs as well as a 33-kDa polypep-
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FIG. 3. NaDodSO4/polyacrylamide gel electrophoresis of solubilized guinea pig brain membrane proteins following photoaffinity
labeling as indicated. Aliquots (1 ml, 800 ,ug of protein) were
incubated with 10 nM [3H]N3DTG in the presence or absence of
various unlabeled drugs at a concentration of 10 ,uM, followed by
washing, irradiation, and solubilization with NaDodSO4. (Left)
Coomassie blue staining. (Right) Fluorography of gel after treatment
with EN3HANCE and exposure to Kodak X-Omat AR film for 14
days at -70°C, showing selective incorporation of label into a Mr
29,000 polypeptide. Molecular weight markers (Sigma) were trypsin
inhibitor (20.1 kDa), carbonic anhydrase (29 kDa), glyceraldehyde3-phosphate dehydrogenase (36 kDa), and bovine serum albumin (66
kDa). (+ )-3-PPP, (+ )-3-(3-hydroxyphenyl)-N-(1-propyl)piperidine.
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FIG. 5. NaDodSO4/polyacrylamide gel electrophoresis demonstrating that photoaffinity-labeled cholate-solubilized receptor is
composed of radiolabeled Mr 29,000 polypeptide in a noncovalently
associated complex. The Mr =150,000 radioactive peak fractions
from Sepharose C1-6B chromatography (Fig. 4) were pooled, concentrated, and electrophoresed on a 12% discontinuous gel. Gel
slices (5 mm) were incubated in 10% Protosol in Aquasol (New
England Nuclear) overnight at 50°C, and then radioactivity was
measured.

2848

Neurobiology: Kavanaugh et al.

tide whose labeling was blocked less effectively by PCPrelated drugs but was strongly inhibited by the benzomorphan (±)-N-allylnormetazocine, for which the a receptor
has a higher affinity (27). It is not clear at present whether
the 33-kDa PCP binding polypeptide from rat brain corresponds to the 29-kDa oa binding subunit identified here in
guinea pig brain by using [3H]N3DTG. This ligand should be
a useful tool to further characterize the structural and
molecular properties of the or receptor and its associated
proteins and to investigate its relation to PCP binding sites in
the brain.
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